Bank of America Maintains Buy Rating on Merck Following Private Meeting with Chief Medical Officer
Bank of America analysts met privately with Merck’s chief medical officer and reaffirmed their 'Buy' rating for the stock, maintaining a $166 price target. The meeting focused heavily on Merck's pipeline developments as its flagship drug Keytruda approaches patent expiration in 2028. Analysts noted that management expressed strong confidence in future growth drivers despite challenges ahead. Keytruda and its newer formulation generated over half of Merck’s Q2 revenue, but the company is counting on new therapies to fill a projected $31 billion gap once exclusivity ends. Recent positive trial results with a personalized cancer vaccine have already boosted investor sentiment, contributing to an 12.5% stock jump in August. The analysts emphasized that upcoming data from Merck’s pipeline over the next year could significantly influence its valuation and long-term growth potential.
Topics: Keytruda patent cliff pharma stock analysis pipeline development